CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 2.395 USD 0.21%
Market Cap: 377.3m USD

Operating Margin
CytomX Therapeutics Inc

24.4%
Current
-167%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.4%
=
Operating Profit
36m
/
Revenue
147.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
CytomX Therapeutics Inc
NASDAQ:CTMX
376.5m USD
24%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.6B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.9B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.3B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

CytomX Therapeutics Inc
Glance View

Market Cap
377.3m USD
Industry
Biotechnology

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).

CTMX Intrinsic Value
0.302 USD
Overvaluation 87%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.4%
=
Operating Profit
36m
/
Revenue
147.6m
What is the Operating Margin of CytomX Therapeutics Inc?

Based on CytomX Therapeutics Inc's most recent financial statements, the company has Operating Margin of 24.4%.

Back to Top